Search Result

Pathways Recommended:	PI3K/Akt/mTOR

Results for "

PI3K p110α

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PI3K (40) Akt (7) Apoptosis (13) Autophagy (8) Biochemical Assay Reagents (1) Cadherin (1) Casein Kinase (4) CDK (1) DNA-PK (7) GLUT (2) Molecular Glues (1) mTOR (14) PAK (1) PERK (1) PROTACs (1) Ras (4) Reference Standards (9)
By Research Areas:	Cancer (37) Infection (1) Inflammation/Immunology (3) Metabolic Disease (5) Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Antibodies

Targets Recommended: PI3K

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-50673

Dactolisib 65+ Cited Publications BEZ235; NVP-BEZ235	PI3K mTOR Autophagy	Cancer
Dactolisib (BEZ235) is an orally active and dual pan-class I *PI3K* and mTOR kinase inhibitor with IC₅₀s of 4 nM/5 nM/7 nM/75 nM, and 20.7 nM for *p110α/p110γ/p110δ/p110β* and mTOR, respectively. Dactolisib (BEZ235) inhibits both mTORC1 and mTORC2.

HY-70063

Buparlisib 85+ Cited Publications BKM120; NVP-BKM120	PI3K Apoptosis	Cancer
Buparlisib (BKM120; NVP-BKM120) is a pan-class I *PI3K* inhibitor, with blood-brain barrier permeability. Buparlisib has IC₅₀s of 52, 166, 116 and 262 nM for *p110α, p110β, p110δ* and *p110γ*, respectively ^[3] .

HY-10297

Omipalisib 15+ Cited Publications GSK2126458; GSK458	PI3K mTOR Autophagy	Cancer
Omipalisib (GSK2126458) is an orally active and highly selective inhibitor of *PI3K* with K_is of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2, respectively. Omipalisib has anti-cancer activity ^[3].

HY-10115

PI-103 30+ Cited Publications	PI3K mTOR DNA-PK Autophagy Apoptosis	Cancer
PI-103 is a potent *PI3K* and mTOR inhibitor with IC₅₀s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for *p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 also inhibits DNA-PK* with an IC50 of 2 nM. PI-103 induces autophagy ^[3] .

HY-10108A

LY294002 hydrochloride Maximum Cited Publications 1120 Publications Verification	PI3K Casein Kinase DNA-PK Apoptosis	Cancer
LY294002 hydrochloride is a potent and broad-spectrum *PI3K* inhibitor, with IC₅₀ values of 0.5, 0.57, and 0.97 μM for *P110α, P110δ* and *P110β, respectively. LY294002 hydrochloride also inhibits CK2* with an IC₅₀ of 98 nM. LY294002 hydrochloride can be used for pancreatic cancer research ^[3].

HY-128574

D927 DS11252927	GLUT PI3K Akt	Metabolic Disease
D927 (DS11252927) is an orally active glucose transporter type 4 (GLUT4) translocation activator with an EC₅₀ of 0.14 μM. D927 enhances the binding affinity of PI3Kα catalytic subunit p110α to canonical RAS proteins (KRAS4A, KRAS4B) and RRAS, RRAS2, MRAS. D927 activates the PI3Kα-AKT pathway (increasing phosphorylation of AKT, p70S6 kinase) without affecting the RAF-ERK1/2 pathway. D927 improves hyperglycemia in type 1 and type 2 diabetes mice model. D927 can be used for the study of glucose homeostasis disorders and diabetes .

HY-15900

Voxtalisib 5 Publications Verification XL765; SAR245409	PI3K mTOR	Cancer
Voxtalisib (XL765) is a potent *PI3K* inhibitor, which has a similar activity toward class I PI3K (IC₅₀s=39, 113, 9 and 43?nM for *p110α, p110β, p110γ* and *p110δ, respectively), also inhibits DNA-PK (IC₅₀=150?nM) and mTOR (IC₅₀=157?nM). Voxtalisib (XL765) inhibits mTORC1* and mTORC2 with IC₅₀s of 160 and 910 nM, respectively.

HY-15245

GSK2636771 5+ Cited Publications	PI3K	Cancer
GSK2636771 is a potent, selective and orally bioavailable inhibitor of PI3Kβ with a K_i of 0.89 nM and an IC₅₀ of 5.2 nM, showing 900-fold selectivity over p110α and p110γ, and 10-fold selectivity over p110δ isoforms.

HY-12030

PIK-90 5 Publications Verification	PI3K DNA-PK	Cancer
PIK-90 is a DNA-PK and *PI3K* inhibitor, which inhibits *p110α, p110γ* and DNA-PK with IC₅₀s of 11, 18 and 13 nM, respectively.

HY-173405

VVD-699	Ras PI3K Akt	Cancer
VVD-699 is a covalent blocker of the *RAS-p110α* interaction with oral activity. VVD-699 inhibits activation of PI3Kα (IC₅₀: 104 nM in H358 cells) . VVD-699 inhibits phosphorylated AKT. VVD-699 can be used for the research of KRAS mutant/amplified cancer .

HY-N6775

Sonolisib 1 Publications Verification PX-866	PI3K	Cancer
Sonolisib (PX-866), an improved Wortmannin analogue, is an oral, irreversible, and pan-isoform inhibitor of *PI3K* (IC₅₀=0.1 nM (p110α), 1.0 nM (p120γ), 2.9 nM (p110δ)). Antitumor activity .

HY-176811

VVD-442	Ras PI3K Akt	Cancer
VVD-442 is an inhibitor targeting PI3Kα. VVD-442 covalently binds to Cys242 in the RAS-binding domain of PI3K p110α, induces conformational changes, and disrupts the interaction between PI3K p110α and RAS proteins. VVD-442 also blocks RAS-mediated *PI3K* activation. VVD-442 can be used in research related to RAS-mutant cancers and HER2-overexpressing cancers .

HY-10115A

PI-103 Hydrochloride 30+ Cited Publications	PI3K mTOR DNA-PK Autophagy Apoptosis	Cancer
PI-103 Hydrochloride is a dual *PI3K* and mTOR inhibitor with IC₅₀s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for *p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 Hydrochloride also inhibits DNA-PK* with an IC50 of 2 nM. PI-103 Hydrochloride induces autophagy ^[3] .

HY-176812

VVD-849	Ras PI3K Akt	Cancer
VVD-849 is a RAS ligand. VVD-849 covalently binds to Cys242 in the RAS-binding domain of **PI3K p110α and promotes RAS/PI3K interaction. VVD-849 partially inhibits pAKT** (S473) in HER2-overexpressing tumors. VVD-849 can be used for the research of cancers such as breast cancer .

HY-108606

PI-828 2 Publications Verification	PI3K Casein Kinase	Cancer
PI-828 is a dual *PI3K* and casein kinase 2 (CK2) inhibitor with IC₅₀s of 173 nM, 149 nM, and 1127 nM for *p110α, CK2, and CK2α2* in lipid kinase assay, respectively .

HY-W1126235

DS02312223 D223	Molecular Glues Ras PI3K GLUT	Metabolic Disease
DS02312223 (D223) is a molecular glue that promotes the binding of RAS to PI3Kα, with a K_d of 0.76 μM for *p110α. DS02312223 increases the binding affinity between GTP-bound KRAS (KRAS-GMPPNP) and p110α* by nearly three orders of magnitude (K_D = 0.017 μM). DS02312223 stimulates the translocation of GLUT4 to the plasma membrane. DS02312223 promotes glucose uptake in the absence of insulin. DS02312223 can be used in diabetes research .

HY-12235

PI-3065 4 Publications Verification	PI3K	Inflammation/Immunology Cancer
PI-3065 is a potent inhibitor of **PI3K p110δ, with IC₅₀ and K_i** values of 5 nM and 1.5 nM, and exhibits less potent activity against p110α, p110β, p110γ with IC₅₀s of 910, 600, >10000 nM.

HY-15180

Buparlisib Hydrochloride 85+ Cited Publications BKM120 Hydrochloride; NVP-BKM120 Hydrochloride	PI3K Apoptosis	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Buparlisib Hydrochloride (BKM120 Hydrochloride) is a CNS-penetrant pan-class I *PI3K* inhibitor, with IC₅₀ of 52 nM/166 nM/116 nM/262 nM for *p110α/p110β/p110δ/p110γ*, respectively.

HY-15244R

Alpelisib (Standard) BYL-719 (Standard)	Reference Standards PI3K Apoptosis	Cancer
Alpelisib (Standard) is the analytical standard of Alpelisib. This product is intended for research and analytical applications. Alpelisib (BYL-719) is a potent, selective, and orally active PI3Kα inhibitor. Alpelisib (BYL-719) shows efficacy in targeting PIK3CA-mutated cancer. Alpelisib (BYL-719) also inhibits p110α/p110γ/p110δ/p110β with IC50s of 5/250/290/1200 nM, respectively. Antineoplastic activity ^[3].

HY-50673A

Dactolisib hydrochloride 60+ Cited Publications BEZ235 hydrochloride; NVP-BEZ235 hydrochloride	PI3K mTOR Autophagy	Cancer
Dactolisib (BEZ235) hydrochloride is an orally active, dual pan-class I PI3K and mTOR inhibitor for *p110α*/γ/δ/β and mTOR with IC₅₀ of 4 nM/5 nM/7 nM/75 nM and 20.7 nM, respectively. Dactolisib hydrochloride (BEZ235) inhibits mTORC1 and mTORC2 .

HY-150309

PI3K-IN-54	PI3K	Cancer
PI3K-IN-54 (compound 10w) is a pan-PI3K inhibitor. The IC₅₀ values of PI3K-IN-54 for p110α, p110β, and p110δ are 0.22 nM, 1.4 nM, and 0.38 nM, respectively. PI3K-IN-54 can be used in cancer research .

HY-103030

PI3K-IN-32	PI3K	Cancer
PI3K-IN-32 is an imidazopyridine derivative with a 3-NH₂ substituent, and also a **PI3K p110α** inhibitor. PI3K-IN-32 is applicable for cancer research .

HY-13504

PIK-293 1 Publications Verification	PI3K	Metabolic Disease Cancer
PIK-293, an analog of IC87114, is a *PI3K* inhibitor, with IC₅₀ values of 0.24 μM, 10 μM, 25 μM and 100 μM for p110δ, p110β, p110γ and p110α, respectively .

HY-163360

PI3Kα-IN-19	PI3K	Cancer
PI3Kα-IN-19 (Compound 1) is a PI3Kα inhibitor with a targeted binding site at the *p110α* catalytic subunit. PI3Kα is one of the most common dysregulated kinases used in cancer research .

HY-157287

(S)-Phe-A110/B319	PI3K	Inflammation/Immunology
(S)-Phe-A110/B319 is a selective binde that has 20-fold higher affinity towards the H1047R mutant of p110α in the p110α/p85α *PI3K* complex .

HY-178812

PI3Kα-IN-27	PI3K PAK mTOR PERK Apoptosis	Cancer
PI3Kα-IN-27 (Compound 50b) is an orally active *PI3K-α* inhibitor, with an IC₅₀ of 40 nM. PI3Kα-IN-27 effectively inhibits *PAK3, p110α, phospho-mTOR* and phospho-ERK1/2. PI3Kα-IN-27 induces early Apoptosis. PI3Kα-IN-27 shows anticancer activity against pancreatic cancer, lung cancer, breast cancer .

HY-70063R

Buparlisib (Standard) BKM120 (Standard); NVP-BKM120 (Standard)	PI3K Apoptosis Reference Standards	Cancer
Buparlisib (Standard) is the analytical standard of Buparlisib. This product is intended for research and analytical applications. Buparlisib (BKM120; NVP-BKM120) is a pan-class I PI3K inhibitor, with IC50s of 52, 166, 116 and 262 nM for p110α, p110β, p110δ and p110γ, respectively.

HY-157288

(R)-Phe-A110/B319	Biochemical Assay Reagents	Metabolic Disease
(R)-Phe-A110/B319, a hapten, is a selective binder to tumor-associated antigens. (R)-Phe-A110/B319 has a 20-fold higher affinity towards the H1047R mutant of p110α in the p110α/p85α PI3K complex. (R)-Phe-A110/B319 can be used for the research of conditional chimeric antigen receptor T (CAR-T) cell activation and tumor targeting .

HY-185205

VVD-484	PI3K Akt	Cancer
VVD-484 is a **PI3K p110α inhibitor with an IC₅₀** of 0.59 μM against human targets.,VVD-484, classified as a "silent ligand", forms a covalent bond with Cys242 of PI3K p110α without disrupting the p110α-KRAS ^G12C interaction. VVD-484 inhibits phosphorylation (S473) of AKT via a RAS-independent pathway. VVD-484 can be used in the research of HER2-overexpressing cancers .

HY-15180R

Buparlisib Hydrochloride (Standard) BKM120 Hydrochloride (Standard); NVP-BKM120 Hydrochloride (Standard)	PI3K Apoptosis Reference Standards	Cancer
Buparlisib (Hydrochloride) (Standard) is the analytical standard of Buparlisib (Hydrochloride). This product is intended for research and analytical applications. Buparlisib Hydrochloride (BKM120 Hydrochloride) is a pan-class I PI3K inhibitor, with IC50 of 52 nM/166 nM/116 nM/262 nM for p110α/p110β/p110δ/p110γ, respectively.

HY-10116

PI-540	PI3K mTOR	Cancer
PI-540 is a bicyclic thienopyrimidine derivative and an orally active PI3K inhibitor. PI-540 has anti-cancer cell proliferation properties and high tissue distribution. PI-540 can inhibit different isoforms of PI3K, with IC₅₀s of 10 nM (P110α), 3510 nM (P110β), 410 nM (P110δ), and 33110 nM (P110γ). PI-540 also inhibits mTOR (IC₅₀: 61 nM) and DNA-PK (IC₅₀: 525 nM) .

HY-10108AR

LY294002 hydrochloride (Standard)	Reference Standards PI3K Casein Kinase DNA-PK Apoptosis	Cancer
LY294002 (hydrochloride) (Standard) is the analytical standard of LY294002 (hydrochloride). This product is intended for research and analytical applications. LY294002 hydrochloride is a potent and broad-spectrum PI3K inhibitor, with IC50 values of 0.5, 0.57, and 0.97 μM for P110α, P110δ and P110β, respectively. LY294002 hydrochloride also inhibits CK2 with an IC50 of 98 nM. LY294002 hydrochloride can be used for pancreatic cancer research ^[3].

HY-15900R

Voxtalisib (Standard) XL765 (Standard); SAR245409 (Standard)	PI3K mTOR Reference Standards	Cancer
Voxtalisib (Standard) is the analytical standard of Voxtalisib. This product is intended for research and analytical applications. Voxtalisib (XL765) is a potent PI3K inhibitor, which has a similar activity toward class I PI3K (IC50s=39, 113, 9 and 43 nM for p110α, p110β, p110γ and p110δ, respectively), also inhibits DNA-PK (IC50=150 nM) and mTOR (IC50=157 nM). Voxtalisib (XL765) inhibits mTORC1 and mTORC2 with IC50s of 160 and 910 nM, respectively.

HY-183741

VVD-844	PI3K Akt	Cancer
VVD-844 is an orally active covalent inhibitor of PI3Kα, which inhibits Pl3Kα/p110α interaction with an IC₅₀ of 4 nM. VVD-844 covalently binds to Cys ²⁴² in the RAS binding domain of p110α, blocking RAS-p110α interaction and inhibiting PI3Kα activity. VVD-844 inhibits PI3Kα signaling activation in HER2-overexpressing cells via a RAS-independent mechanism. VVD-844 suppresses tumor growth in mouse. VVD-844 can be used for the research of cancers .

HY-10115R

PI-103 (Standard)	Reference Standards PI3K mTOR DNA-PK Autophagy Apoptosis	Cancer
PI-103 (Standard) is the analytical standard of PI-103. This product is intended for research and analytical applications. PI-103 is a potent PI3K and mTOR inhibitor with IC50s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 also inhibits DNA-PK with an IC50 of 2 nM. PI-103 induces autophagy ^[3] .

HY-10115AR

PI-103 Hydrochloride (Standard)	Reference Standards PI3K mTOR DNA-PK Autophagy Apoptosis	Cancer
PI-103 (Hydrochloride) (Standard) is the analytical standard of PI-103 (Hydrochloride). This product is intended for research and analytical applications. PI-103 Hydrochloride is a dual PI3K and mTOR inhibitor with IC50s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 Hydrochloride also inhibits DNA-PK with an IC50 of 2 nM. PI-103 Hydrochloride induces autophagy ^[3] .

HY-179623

PI3Kα-IN-29	PI3K mTOR Akt CDK Cadherin	Cancer
PI3Kα-IN-29 is a potent, orally active and selective PI3Kα with an IC₅₀ of 2.5 nM. PI3Kα-IN-29 exhibits >400-fold selectivity over PI3Kβ/δ/γ/mTOR. PI3Kα-IN-29 selectively degrades the H1047R mutant p110α protein and inhibits PI3Kα kinase activity. PI3Kα-IN-29 suppresses *PI3K/AKT/mTOR* signaling, induces G1 arrest, and inhibits migration. PI3Kα-IN-29 inhibits tumor growth in a T47 mouse model. PI3Kα-IN-29 can be used for the research of breast cancer .

HY-15245R

GSK2636771 (Standard)	PI3K	Cancer
GSK2636771 (Standard) is the analytical standard of GSK2636771. This product is intended for research and analytical applications. GSK2636771 is a potent, selective and orally bioavailable inhibitor of PI3Kβ with a Ki of 0.89 nM and an IC50 of 5.2 nM, showing 900-fold selectivity over p110α and p110γ, and 10-fold selectivity over p110δ isoforms.

HY-180261

GP262	PROTACs mTOR PI3K Apoptosis	Cancer
GP262 is a PI3K/mTOR PROTAC degrader targeting PI3Kγ, PI3Kα and mTOR with DC₅₀ values of 42.23 nM, 227.4 nM and 45.4 nM, respectively in MDA-MB-231 cells. GP262 induces degradation of p110α and p110γ with a DC₅₀ of 227.4 and 42.23 nM. GP262 efficient modulates the PI3K/AKT/mTOR pathway, achieving degradation through the ubiquitin-proteasome system (UPS). GP262 also exhibits robust antiproliferative activity and induces apoptosis in vitro. GP262 exhibits tumor growth suppression capability and biosafety profile. GP262 can be used for leukemia and triple-negative breast cancer (TNBC) .

HY-108606R

PI-828 (Standard)	Reference Standards PI3K Casein Kinase	Cancer
PI-828 (Standard) is the analytical standard of PI-828 (HY-108606). This product is intended for research and analytical applications. PI-828 is a dual PI3K and casein K_inase 2 (CK2) inhibitor with IC₅₀s of 173 nM, 149 nM, and 1127 nM for p110α, CK2, and CK2α2 in lipid K_inase assay, respectively .

HY-10297R

Omipalisib (Standard) GSK2126458 (Standard); GSK458 (Standard)	Reference Standards PI3K mTOR Autophagy	Cancer
Omipalisib (Standard) is the analytical standard of Omipalisib (HY-10297). This product is intended for research and analytical applications. Omipalisib (GSK2126458) is an orally active and highly selective inhibitor of PI3K with Kis of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2, respectively. Omipalisib has anti-cancer activity ^[3].

Cat. No.	Product Name

HY-L015

PI3K/Akt/mTOR Compound Library	1,049 compounds
The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials. MCE owns a unique collection of 1,049 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

PI3K/Akt/mTOR Compound Library

1,049 compounds

The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.

MCE owns a unique collection of 1,049 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

Host:	Rabbit (3)
Reactivity:	Human (3) Rat (3) Mouse (3)
Application:	ICC/IF (3) IP (3) WB (3) ELISA (1)
Isotype:	IgG (3)
Conjugation:	Non-conjugated (3)
Clonality:	Monoclonal (3) Recombinant (2)
Modification:	Unmodified (3)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P81162

	PI3 Kinase p110 alpha/PIK3CA Antibody (YA3537) PI3 kinase p110 subunit alpha; caPI3K; MGC142161; MGC142163; p110 alpha; Phosphatidylinositol 3 kinase catalytic alpha polypeptide; Phosphatidylinositol 3 kinase catalytic 110 KD alpha; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha isoform; Phosphoinositide 3 kinase catalytic alpha polypeptide; PI3 kinase p110 subunit alpha; PI3K; PI3KC A; PIK3C A; PK3CA; PtdIns 3 kinase p110; PI3-kinase p110α; PI3-kinase p110 subunit alpha; PI 3 Kinase catalytic subunit alpha; PK3CA_HUMAN; PI3 kinase p110α.	WB, ICC/IF, IP	Human, Mouse, Rat
	PI3 Kinase p110 alpha/PIK3CA Antibody (YA3537) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PI3 Kinase p110 alpha/PIK3CA.

HY-P81162A

	PI3 Kinase p110 alpha/PIK3CA Antibody (PBS only) PI3 kinase p110 subunit alpha; caPI3K; MGC142161; MGC142163; p110 alpha; Phosphatidylinositol 3 kinase catalytic alpha polypeptide; Phosphatidylinositol 3 kinase catalytic 110 KD alpha; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha isoform; Phosphoinositide 3 kinase catalytic alpha polypeptide; PI3 kinase p110 subunit alpha; PI3K; PI3KC A; PIK3C A; PK3CA; PtdIns 3 kinase p110; PI3-kinase p110α; PI3-kinase p110 subunit alpha; PI 3 Kinase catalytic subunit alpha; PK3CA_HUMAN; PI3 kinase p110α.	WB, ICC/IF, IP	Human, Mouse, Rat
	PI3 Kinase p110 alpha/PIK3CA Antibody (PBS only) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PI3 Kinase p110 alpha/PIK3CA.

HY-P86078

	PI3 Kinase p110 alpha/PIK3CA Antibody (YA5770) 5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha; 5-bisphosphate 3-kinase catalytic subunit alpha isoform; caPI3K; CLOVE; CWS5; MCAP; MCM; MCMTC; MGC142161; MGC142163; p110 alpha; p110alpha; Phosphatidylinositol 3 kinase catalytic alpha polypeptide; Phosphatidylinositol 3 kinase catalytic 110 KD alpha; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha isoform; Phosphatidylinositol 4,5 bisphosphate 3 kinase 110 kDa catalytic subunit alpha; Phosphatidylinositol-4; Phosphoinositide 3 kinase catalytic alpha polypeptide; PI 3 Kinase catalytic subunit alpha; PI3 kinase p110 subunit alpha; PI3-kinase subunit alpha; PI3K; PI3K-alpha; PI3KC A; PIK3C A; PIk3ca; PK3CA; PK3CA_HUMAN; PtdIns 3 kinase p110; PtdIns-3-kinase subunit alpha; PtdIns-3-kinase subunit p110-alpha; Serine/threonine protein kinase PIK3CA	WB, ICC/IF, IP, ELISA	Human, Mouse, Rat
	PI3 Kinase p110 alpha/PIK3CA Antibody (YA5770) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PI3 Kinase p110 alpha/PIK3CA.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: